Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Antimicrobial agents and chemotherapy - 1 Feb 2001

Blondeau J M, Zhao X, Hansen G, Drlica K

Abstract excerpt

The mutant prevention concentration (MPC) represents a threshold above which the selective proliferation of resistant mutants is expected to occur only rarely. A provisional MPC (MPC(pr)) was defined and measured for five fluoroquinolones with clinical isolates of Streptococcus pneumoniae. Based on their potential for restricting the selection of resistant mutants, the five fluoroquinolones, in descending order,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to DNA, Bacterial
Share to Fluoroquinolones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microbial Sensitivity Tests

Share to Mutation

Share to Pneumococcal Infections

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Streptococcus pneumoniae

Source

Open in PubMed Open full text

Identifiers

PMID: 11158737
DOI: 10.1128/AAC.45.2.433-438.2001
PMCID: PMC90309

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.PMID 11158737Read ↗

Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Semantic proximity Read ↗

[Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].Semantic proximity Read ↗

Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.Semantic proximity Read ↗

Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutants of Streptococcus pneumoniae.Semantic proximity Read ↗

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.Semantic proximity Read ↗

Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus.Semantic proximity Read ↗

Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Semantic proximity Read ↗

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis.Semantic proximity Read ↗

New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.Semantic proximity Read ↗

Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.Semantic proximity Read ↗

Therapeutic options in an era of decreasing antimicrobial susceptibility.Semantic proximity Read ↗

Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.